Efficacy and safety of adding evogliptin versus sitagliptin for metformin‐treated patients with type 2 diabetes: A 24‐week randomized, controlled trial with open label extension

AIMS: This trial consisted of a 24‐week multicentre, randomized, double‐blind, double‐dummy, active‐controlled study and a 52‐week open label extension study to assess the efficacy and safety of evogliptin, a novel dipeptidyl peptidase‐4 inhibitor, compared to sitagliptin in patients with type 2 dia...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Sang‐Mo, Park, Cheol‐Young, Hwang, Dong‐Min, Han, Kyung Ah, Lee, Chang Beom, Chung, Choon Hee, Yoon, Kun‐Ho, Mok, Ji‐Oh, Park, Kyong Soo, Park, Sung‐Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412933/
https://www.ncbi.nlm.nih.gov/pubmed/28058750
http://dx.doi.org/10.1111/dom.12870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412933/
https://www.ncbi.nlm.nih.gov/pubmed/28058750
http://dx.doi.org/10.1111/dom.12870

Ejemplares similares